Friday 18 November 2016

TherapeuticsMD (TXMD) Misses Q3 EPS by 2c

Access the best approaches Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

TherapeuticsMD (NYSE: TXMD) reported Q3 EPS of ($0.13), $0.02 more awful than the examiner gauge of ($0.11). Income for the quarter came in at $5.53 million versus the agreement gauge of $5.76 million.

"We are gaining great ground this year propelling our pipeline and upgrading our business abilities concentrated on ladies' wellbeing. Amid the quarter, we effectively finished the accommodation of our NDA for TX-004HR as a novel treatment for direct to extreme dyspareunia, a side effect of VVA because of menopause, and we kept continuous pre-commercialization exercises for this vital item," said TherapeuticsMD CEO Robert G. Finizio. "We now avidly anticipate the topline information from our Replenish Trial for TX-001HR in the final quarter of 2016, our second novel hormone treatment program, which, if endorsed, would be the first and final FDA-affirmed bio-indistinguishable mix of estradiol and progesterone for the treatment of direct to-serious vasomotor manifestations because of menopause."

For profit history and income related information on TherapeuticsMD (TXMD) click here.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.